cERBB-2/Her-2 Neu在子宫癌肉瘤中的过度表达及其预后意义。

IF 1.1 Q4 PATHOLOGY
Huseyin Salih Semiz, Emel Ebru Pala, Behzat Can, Elif Atag, Hatice Gungor, Muzaffer Sanci
{"title":"cERBB-2/Her-2 Neu在子宫癌肉瘤中的过度表达及其预后意义。","authors":"Huseyin Salih Semiz,&nbsp;Emel Ebru Pala,&nbsp;Behzat Can,&nbsp;Elif Atag,&nbsp;Hatice Gungor,&nbsp;Muzaffer Sanci","doi":"10.5146/tjpath.2022.01588","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>There is not enough data in the literature regarding Her-2 overexpression in uterine carcinosarcomas or its association with the prognosis. The aim of this study was to determine the Her-2 overexpression rate in uterine carcinosarcoma and to evaluate its relationship with the prognosis.</p><p><strong>Material and method: </strong>Her-2 protein and gene status were evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively, in hysterectomy specimens from 51 patients with uterine carcinosarcoma.</p><p><strong>Results: </strong>Her-2 protein expression in the epithelial component was negative in 42 patients (score 0 in 33 cases, score (+1) in 9 cases), score (+2) in 7 patients and score (+3) in 2 patients. None of the patients had Her-2 protein expression within the sarcomatous component of the tumors. Her-2 gene was not amplified in epithelial or mesenchymal tumor areas according to the FISH method. There was no difference between the Her-2 overexpression negative and positive groups in terms of disease-free survival (DFS) and overall survival (OS). Her-2 overexpression was significantly higher in tumors of patients diagnosed at 65 years or older (p=0.046).</p><p><strong>Conclusion: </strong>In our study, no relationship could be shown between Her-2 overexpression and prognosis in uterine carcinosarcoma. More comprehensive studies are needed to illustrate the relationship between Her-2 overexpression and carcinosarcoma prognosis.</p>","PeriodicalId":45415,"journal":{"name":"Turkish Journal of Pathology","volume":"39 1","pages":"55-63"},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518127/pdf/","citationCount":"0","resultStr":"{\"title\":\"cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.\",\"authors\":\"Huseyin Salih Semiz,&nbsp;Emel Ebru Pala,&nbsp;Behzat Can,&nbsp;Elif Atag,&nbsp;Hatice Gungor,&nbsp;Muzaffer Sanci\",\"doi\":\"10.5146/tjpath.2022.01588\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>There is not enough data in the literature regarding Her-2 overexpression in uterine carcinosarcomas or its association with the prognosis. The aim of this study was to determine the Her-2 overexpression rate in uterine carcinosarcoma and to evaluate its relationship with the prognosis.</p><p><strong>Material and method: </strong>Her-2 protein and gene status were evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively, in hysterectomy specimens from 51 patients with uterine carcinosarcoma.</p><p><strong>Results: </strong>Her-2 protein expression in the epithelial component was negative in 42 patients (score 0 in 33 cases, score (+1) in 9 cases), score (+2) in 7 patients and score (+3) in 2 patients. None of the patients had Her-2 protein expression within the sarcomatous component of the tumors. Her-2 gene was not amplified in epithelial or mesenchymal tumor areas according to the FISH method. There was no difference between the Her-2 overexpression negative and positive groups in terms of disease-free survival (DFS) and overall survival (OS). Her-2 overexpression was significantly higher in tumors of patients diagnosed at 65 years or older (p=0.046).</p><p><strong>Conclusion: </strong>In our study, no relationship could be shown between Her-2 overexpression and prognosis in uterine carcinosarcoma. More comprehensive studies are needed to illustrate the relationship between Her-2 overexpression and carcinosarcoma prognosis.</p>\",\"PeriodicalId\":45415,\"journal\":{\"name\":\"Turkish Journal of Pathology\",\"volume\":\"39 1\",\"pages\":\"55-63\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518127/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Journal of Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5146/tjpath.2022.01588\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5146/tjpath.2022.01588","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:关于子宫癌肉瘤中Her-2的过度表达及其与预后的关系,文献中没有足够的数据。本研究的目的是确定子宫癌肉瘤中Her-2的过表达率,并评估其与预后的关系。材料和方法:分别用免疫组织化学(IHC)和荧光原位杂交(FISH)方法对51例子宫癌肉瘤患者的子宫切除标本中Her-2蛋白和基因状态进行评估。结果:42例患者上皮成分中Her-2蛋白表达呈阴性(33例评分0,9例评分(+1)),7例评分(+2),2例评分(+3)。没有一名患者在肿瘤的肉瘤成分中有Her-2蛋白表达。根据FISH方法,Her-2基因在上皮或间充质肿瘤区域未扩增。Her-2过表达阴性组和阳性组在无病生存期(DFS)和总生存期(OS)方面没有差异。Her-2过表达在65岁或65岁以上诊断的肿瘤患者中显著较高(p=0.046)。结论:在我们的研究中,Her-2过度表达与子宫癌肉瘤的预后之间没有关系。需要更全面的研究来阐明Her-2过表达与癌肉瘤预后之间的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.

Objective: There is not enough data in the literature regarding Her-2 overexpression in uterine carcinosarcomas or its association with the prognosis. The aim of this study was to determine the Her-2 overexpression rate in uterine carcinosarcoma and to evaluate its relationship with the prognosis.

Material and method: Her-2 protein and gene status were evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively, in hysterectomy specimens from 51 patients with uterine carcinosarcoma.

Results: Her-2 protein expression in the epithelial component was negative in 42 patients (score 0 in 33 cases, score (+1) in 9 cases), score (+2) in 7 patients and score (+3) in 2 patients. None of the patients had Her-2 protein expression within the sarcomatous component of the tumors. Her-2 gene was not amplified in epithelial or mesenchymal tumor areas according to the FISH method. There was no difference between the Her-2 overexpression negative and positive groups in terms of disease-free survival (DFS) and overall survival (OS). Her-2 overexpression was significantly higher in tumors of patients diagnosed at 65 years or older (p=0.046).

Conclusion: In our study, no relationship could be shown between Her-2 overexpression and prognosis in uterine carcinosarcoma. More comprehensive studies are needed to illustrate the relationship between Her-2 overexpression and carcinosarcoma prognosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.90
自引率
10.00%
发文量
23
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信